Profound Medical to Participate in 10th Annual BIG10 Conference
News provided byProfound Medical Corp · 1 min read
TORONTO, Sept. 03, 2026 /CourierPR/ -- Profound Medical, a commercial-stage medical device company known for its innovative interventional MRI (iMRI) procedures, will participate in the 10th Annual Best Ideas Growth Conference (BIG10) organized by Lake Street Capital Markets in New York City on September 10, 2026. The event will feature one-on-one investor meetings, with no webcast available.
Profound Medical’s flagship platform, TULSA-PRO®, allows physicians to perform MRI-guided, incision-free prostate ablation. This technology enables real-time visualization, ablation, and confirmation of therapy, supporting personalized treatment strategies ranging from whole-gland to focal therapy. By minimizing the side effects typically associated with surgery or radiation, such as urinary incontinence and erectile dysfunction, TULSA-PRO provides a more patient-friendly treatment option.
In addition to TULSA-PRO, Profound Medical commercializes Sonalleve®, an MRI-guided therapy for pain management in bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions like uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy without incisions, blood loss, overnight hospital stay, and offers faster recovery, including uterine-sparing treatment that may preserve fertility. The company is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved in major global markets. TULSA-PRO is cleared by the FDA for transurethral ultrasound ablation (TULSA) of prostate tissue in the United States and various jurisdictions, including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as Humanitarian Device Exemption (HDE) for treating osteoid osteomas in the extremities and is cleared or approved in the Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound Medical is advancing the future of MRI-guided therapy, expanding access to precise, personalized, and incision-free treatment options worldwide.